CN105263484B - 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途 - Google Patents

包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途 Download PDF

Info

Publication number
CN105263484B
CN105263484B CN201480028924.0A CN201480028924A CN105263484B CN 105263484 B CN105263484 B CN 105263484B CN 201480028924 A CN201480028924 A CN 201480028924A CN 105263484 B CN105263484 B CN 105263484B
Authority
CN
China
Prior art keywords
dihydroquercetin
metformin
pharmaceutically acceptable
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480028924.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263484A (zh
Inventor
清野邦彦
大西健司
永滨康晴
渡边隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Nutrition
Original Assignee
Ageing Nutrition Institute
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ageing Nutrition Institute, Otsuka Pharmaceutical Co Ltd filed Critical Ageing Nutrition Institute
Publication of CN105263484A publication Critical patent/CN105263484A/zh
Application granted granted Critical
Publication of CN105263484B publication Critical patent/CN105263484B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
CN201480028924.0A 2013-05-24 2014-05-23 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途 Active CN105263484B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013110278 2013-05-24
JP2013-110278 2013-05-24
PCT/JP2014/064354 WO2014189152A1 (en) 2013-05-24 2014-05-23 Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN105263484A CN105263484A (zh) 2016-01-20
CN105263484B true CN105263484B (zh) 2018-08-03

Family

ID=50980347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028924.0A Active CN105263484B (zh) 2013-05-24 2014-05-23 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途

Country Status (14)

Country Link
US (4) US9808440B2 (enExample)
EP (1) EP3003296B1 (enExample)
JP (2) JP6440212B2 (enExample)
KR (1) KR102182946B1 (enExample)
CN (1) CN105263484B (enExample)
AR (1) AR096402A1 (enExample)
AU (1) AU2014269401A1 (enExample)
CA (1) CA2912881A1 (enExample)
HK (1) HK1223304A1 (enExample)
PH (1) PH12015502616A1 (enExample)
RU (2) RU2018135973A (enExample)
SG (1) SG11201509555UA (enExample)
TW (2) TWI688387B (enExample)
WO (1) WO2014189152A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10468144B2 (en) 2014-08-19 2019-11-05 Nuscale Power, Llc Spent fuel storage rack
CN105330575A (zh) * 2015-10-14 2016-02-17 吉林海格力斯医药生物科技发展有限公司 一种用于治疗放疗、化疗引起的骨髓损伤的化合物
MX2019003725A (es) 2016-09-30 2019-08-12 Laboratorios Silanes S A De C V Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
CN108078938A (zh) * 2018-01-15 2018-05-29 栾晓民 一种二氢槲皮素制剂的制备方法及应用
EP3784650B1 (en) 2018-04-25 2023-09-06 Charles R. Drew University of Medicine and Science N-phenyl-n'-(4-{[6-(1h-imidazol-1-yl)-4-pyrimidinyl]amino}phenyl)urea derivatives as mct4 inhibitors for the treatment of cancer
KR102349477B1 (ko) * 2019-08-30 2022-01-10 (주)프론트바이오 바이구아나이드 계열 화합물 및 플라본, 하이드록시플라본, 플라바논, 플라본 유도체, 하이드록시플라본 유도체, 플라바논 유도체의 복합제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
PT4069254T (pt) * 2020-02-25 2024-10-10 Otsuka Pharma Co Ltd Formas sólidas de dosagem oral compreendendo decitabina e cedazuridina
CN111467332B (zh) * 2020-03-31 2021-08-24 中国科学院苏州生物医学工程技术研究所 低温等离子体与二甲双胍联用的应用
RU2740946C1 (ru) * 2020-06-30 2021-01-21 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Средство для снижения патоморфологических изменений при гиперплазии предстательной железы
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer
CN115154458B (zh) * 2022-07-25 2023-11-10 天水师范学院 一种槲皮素-盐酸二甲双胍复合降糖药物的制备方法
WO2024233616A1 (en) * 2023-05-11 2024-11-14 Wainer Irving W Method for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166008A1 (en) * 2011-06-02 2012-12-06 Leshkov Sergey Yurievich Combination for treatment of diabetes mellitus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3523287B2 (ja) * 1993-02-26 2004-04-26 丸善製薬株式会社 発癌プロモーション抑制剤
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
DE102008029460A1 (de) 2008-06-20 2009-12-31 Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' Taxifolinderivate zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Störungen des zentralen Nervensystems
US20100189653A1 (en) 2008-10-10 2010-07-29 Wendye Robbins Pyrone analogs for therapeutic treatment
KR20120080579A (ko) * 2009-08-25 2012-07-17 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 치료와 예방에 있어 메트포르민의 사용
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
JP5645796B2 (ja) 2011-11-21 2014-12-24 東京エレクトロン株式会社 液処理装置及び液処理方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166008A1 (en) * 2011-06-02 2012-12-06 Leshkov Sergey Yurievich Combination for treatment of diabetes mellitus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and hela tumor cells;Majid Y. Moridani等;《chemico-biological interaction》;20021231;第139卷;251-264 *
二甲双胍对人胰腺癌细胞增殖与凋亡的影响;唐曦平 等;《中国癌症杂志》;20121231;第22卷(第11期);801-807 *
槲皮素诱导人胰癌细胞株canpan-2凋亡的实验研究;牛壮 等;《中国实验诊断学》;20071031;第11卷(第10期);1346-1348 *

Also Published As

Publication number Publication date
RU2015155283A (ru) 2017-06-29
KR102182946B1 (ko) 2020-11-25
TWI667021B (zh) 2019-08-01
HK1223304A1 (zh) 2017-07-28
JP2016522202A (ja) 2016-07-28
EP3003296A1 (en) 2016-04-13
JP2019048850A (ja) 2019-03-28
JP6440212B2 (ja) 2018-12-19
SG11201509555UA (en) 2015-12-30
AU2014269401A1 (en) 2016-01-21
EP3003296B1 (en) 2018-10-10
RU2018135973A (ru) 2018-11-14
RU2671488C2 (ru) 2018-11-01
US20180036280A1 (en) 2018-02-08
WO2014189152A1 (en) 2014-11-27
US20180353466A1 (en) 2018-12-13
CN105263484A (zh) 2016-01-20
US9808440B2 (en) 2017-11-07
US20160101082A1 (en) 2016-04-14
CA2912881A1 (en) 2014-11-27
US20180050014A1 (en) 2018-02-22
US10292962B2 (en) 2019-05-21
TW201906603A (zh) 2019-02-16
RU2018135973A3 (enExample) 2022-03-04
AR096402A1 (es) 2015-12-30
PH12015502616A1 (en) 2016-02-29
TW201536275A (zh) 2015-10-01
KR20160013164A (ko) 2016-02-03
TWI688387B (zh) 2020-03-21
JP6754071B2 (ja) 2020-09-09

Similar Documents

Publication Publication Date Title
CN105263484B (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途
CN103282037B (zh) 抗肿瘤生物碱的联合治疗
KR20130015669A (ko) 암의 재발 또는 전이의 억제용 약제학적 조성물
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
CN102065865B (zh) 多发性骨髓瘤治疗
EA033744B1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
TW200823218A (en) Combination drug
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
US12226454B2 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
JP7535285B2 (ja) 腫瘍関連マクロファージ賦活化剤
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
EP3417864A1 (en) Immunosuppression weaning agent and use thereof
JPWO2009110415A1 (ja) 併用剤
JP2024538411A (ja) 心臓保護の方法
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
CN118555959A (zh) 心脏保护方法
TW200940546A (en) Combination drug

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170308

Address after: Saitama Prefecture, Japan

Applicant after: Institute of nutrition

Address before: Tokyo, Japan

Applicant before: Otsuka Pharmaceutical Co., Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant